Clinical Trial Update: GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds [Phase 4]

View source ↗

Summary

Phase 4 open-label study evaluating GrafixCORE for complex diabetic foot wounds has completed, reporting safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• GrafixCORE

Snippet

Sponsor: Osiris Therapeutics | Conditions: Complex Diabetic Foot Wounds | Phase 4 | Status: COMPLETED